HeartSciences is a healthcare IT company that modernizes ECG data management and integrates AI-based diagnostics into clinical workflows. Its primary product, MyoVista Insights, is a cloud-native SaaS platform that centralizes ECG storage and streamlines interpretation workflows. The platform is vendor-agnostic, allowing healthcare providers to connect existing third-party ECG devices and integrate data into electronic medical record systems like Epic. Because MyoVista Insights is classified as a Medical Device Data System, it did not require FDA 510(k) premarket clearance for commercialization. HeartSciences operates the platform as an AI-ECG marketplace, hosting both proprietary and third-party algorithms. These algorithms identify cardiac conditions that traditional ECGs often miss, such as valve abnormalities or coronary artery disease. The company generates revenue through one-time installation fees, recurring SaaS subscriptions, and fees from AI algorithm usage. HeartSciences is also developing the MyoVista wavECG, a 12-lead hardware device designed to embed AI algorithms at the point of care, which is currently awaiting FDA clearance. The company’s strategy is to serve as the infrastructure layer for AI-ECG adoption by expanding its algorithm marketplace and scaling into outpatient clinics and international markets like India.